Cytokinetics: 18.4% YTD Gain Masks Balance Sheet and Commercial Risks

What happened

Cytokinetics shares have risen 18.4% year-to-date, driven by Myqorzo's FDA approval, early launch momentum, and expanding market opportunities. However, the DeepValue master report cautions that this optimism ignores a heavily leveraged balance sheet, negative equity, and an entrenched competitor in Camzyos, which already treated over 12,500 U.S. patients. Myqorzo's REMS advantage has been eroded by Camzyos' label simplification, and the company's cash burn remains high, with a 4.5% royalty on future sales locked in. The market's bullish positioning is crowded, and any launch disappointment or failure of the upcoming ACACIA nHCM trial in Q2 2026 could trigger a sharp reversal.

Implication

Cytokinetics needs to demonstrate Myqorzo is gaining meaningful share from Camzyos and that ACACIA succeeds to justify the current ~$7.7B market cap. Without clear evidence, the risk/reward skews to downside, and investors should consider reducing exposure.

Thesis delta

The original thesis hinged on FDA approval as a catalyst, which has now passed. The market is pricing in a rapid, high-share launch and successful nHCM expansion, but the DeepValue analysis finds these assumptions aggressive given competitive and financial headwinds. The delta is a shift from binary regulatory risk to ongoing commercial execution risk, with a less favorable risk/reward at current levels.